Home > Insider Trading > Filing (0001181431-10-031733)

Filing Details

Accession Number:: 0001181431-10-031733
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2010-06-07 13:00:00
Reporting Period:: 2010-06-03

Filing Date:: 2010-06-07
Accepted Time:: 2010-06-07 17:14:18
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1487371	Genmark Diagnostics Inc.	GNMK	Surgical & Medical Instruments & Apparatus (3841)	272053069

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1134540	M Christopher Gleeson	757 S. Raymond Avuene Pasadena CA 91105		Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2010-06-03	31,185	$0.00	31,185	No	4	J	Direct
Common Stock	Acquisiton	2010-06-03	229,232	$0.00	229,232	No	4	J	Indirect	Gleeson Family Trust
Common Stock	Acquisiton	2010-06-03	1,333,333	$6.00	1,562,565	No	4	P	Indirect	Gleeson Family Trust

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	J	Direct
No	4	J	Indirect	Gleeson Family Trust
No	4	P	Indirect	Gleeson Family Trust

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Acquisiton	2010-06-03	25,080	$0.00	25,080	$6.93
Common Stock	Stock Option (Right to Buy)	Acquisiton	2010-06-03	25,080	$0.00	25,080	$6.49
Common Stock	Stock Option (Right to Buy)	Acquisiton	2010-06-03	4,821	$0.00	4,821	$6.49
Common Stock	Warrant	Acquisiton	2010-06-03	88,317	$0.00	88,317	$9.98

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
25,080		2019-09-24	No	4	J	Direct
25,080		2019-12-22	No	4	J	Direct
4,821	2010-06-03	2019-12-22	No	4	J	Direct
88,317	2010-06-03		No	4	J	Direct

Footnotes

Received in exchange for ordinary shares of Osmetech plc in connection with the reorganization of GenMark Diagnostics, Inc. The reorganization resulted in GenMark becoming the parent company of Osmetech, GenMark's parent company prior to the reorganization, through a scheme of arrangement under Part 26 of the U.K. Companies Act of 2006, but did not alter the proportionate interests of security holders. The number of shares issuable pursuant to the reorganization was determined pursuant to an exchange ratio of 230 ordinary shares of Osmetech for one share of GenMark common stock.
Mr. Gleeson is the trustee of the Gleeson Family Trust and may be deemed to have beneficial ownership of this securities, except to the extent of any indirect pecuniary interest in his distributive shares therein.
Received in exchange for options to purchase ordinary shares of Osmetech plc. The number of options issuable pursuant to the reorganization was determined pursuant to an exchange ratio of 230 options to purchase ordinary shares of Osmetech for an option to purchase one share of GenMark common stock.
33% of the option shares vest and become exercisable on January 20, 2010, January 20, 2011 and January 20, 2012 respectively.
11,494 of the option shares have vested and became exercisable and the remaining option shares vest and become exercisable in 26 monthly installments beginning on June 23, 2009.
Received in exchange for warrants to purchase ordinary shares of Osmetech plc. The number of warrants issuable pursuant to the reorganization was determined pursuant to an exchange ratio of 230 warrants to purchase ordinary shares of Osmetech for a warrant to purchase one share of GenMark common stock.
The warrant expires on the earlier of (i) 60 days after Mr. Gleeson is no longer a director of the Issuer and (ii) June 30, 2012.